Overview

An Open-label Extension Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal Epilepsy

Status:
Completed
Trial end date:
2020-11-01
Target enrollment:
Participant gender:
Summary
The purpose of study EP0073 is to assess the long-term safety, tolerability, and efficacy during 5 years of treatment with the drug UCB0942 in patients with highly drug-resistant focal epilepsy. Also, the effects of UCB0942 on the patient's quality of life will be explored.
Phase:
Phase 2
Details
Lead Sponsor:
UCB Biopharma S.P.R.L.